Only in Titles

Search results for: Aurora B Antibody

paperclip

#35735358   2022/06/05 To Up

Strategies to Screen Anti-AQP4 Antibodies from Yeast Surface Display Libraries.

A rapid and effective method to identify disease-specific antibodies from clinical patients is important for understanding autoimmune diseases and for the development of effective disease therapies. In neuromyelitis optica (NMO), the identification of antibodies targeting the aquaporin-4 (AQP4) membrane protein traditionally involves the labor-intensive and time-consuming process of single B-cell sorting, followed by antibody cloning, expression, purification, and analysis for anti-AQP4 activity. To accelerate patient-specific antibody discovery, we compared two unique approaches for screening anti-AQP4 antibodies from yeast antibody surface display libraries. Our first approach, cell-based biopanning, has strong advantages for its cell-based display of native membrane-bound AQP4 antigens and is inexpensive and simple to perform. Our second approach, FACS screening using solubilized AQP4 antigens, permits real-time population analysis and precision sorting for specific antibody binding parameters. We found that both cell-based biopanning and FACS screening were effective for the enrichment of AQP4-binding clones. These screening techniques will enable library-scale functional interrogation of large natively paired antibody libraries for comprehensive analysis of anti-AQP4 antibodies in clinical samples and for robust therapeutic discovery campaigns.
Aric Huang, Wei Jin, Ahmed S Fahad, Brooklyn K Mussman, Grazia Paola Nicchia, Bharat Madan, Matheus Oliveira de Souza, J Daniel Griffin, Jeffrey L Bennett, Antonio Frigeri, Cory J Berkland, Brandon J DeKosky

2485 related Products with: Strategies to Screen Anti-AQP4 Antibodies from Yeast Surface Display Libraries.

1 mg0.1 mg1 mL1 mg100 μg1 mg1 ml1 mg0.2 mg0.2 mg1 mL1 mg

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

#35717989   // To Up

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed within 12 months of first-line therapy are at high risk for poor outcomes with current standard of care, platinum-based salvage immunochemotherapy and autologous haematopoietic stem cell transplantation (HSCT). Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has previously demonstrated efficacy and manageable safety in third-line or later LBCL. In this Article, we report a prespecified interim analysis of liso-cel versus standard of care as second-line treatment for primary refractory or early relapsed (within 12 months after response to initial therapy) LBCL.
Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, David G Maloney, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Lara Stepan, Ken Ogasawara, Timothy Mack, Jeremy S Abramson,

1483 related Products with: Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

1 kit1 kit1 mL96 tests1 mL2 Pieces/Box100ug Lyophilized

Related Pathways

paperclip

#35496758   2022/04/26 To Up

A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse.

Recombinant human immunoglobulin M22 (rHIgM22) has promoted remyelination in animal models and was well tolerated in people with clinically stable multiple sclerosis.
Benjamin M Greenberg, James D Bowen, Enrique Alvarez, Moses Rodriguez, Anthony O Caggiano, Arthur E Warrington, Ping Zhao, Andrew Eisen

1586 related Products with: A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse.

16 Arrays/Slide

Related Pathways

    No related Items
paperclip

#35476650   // To Up

Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.

Respiratory syncytial virus (RSV), a major cause of illness and death in infants worldwide, could be prevented by vaccination during pregnancy. The efficacy, immunogenicity, and safety of a bivalent RSV prefusion F protein-based (RSVpreF) vaccine in pregnant women and their infants are uncertain.
Eric A F Simões, Kimberly J Center, Alan T N Tita, Kena A Swanson, David Radley, John Houghton, Stephanie B McGrory, Emily Gomme, Marquita Anderson, John P Roberts, Daniel A Scott, Kathrin U Jansen, William C Gruber, Philip R Dormitzer, Alejandra C Gurtman

2023 related Products with: Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.

100100100 100100ug Lyophilized50ul1 Set1 Set1 Set1 Set1 Set1 Set

Related Pathways

paperclip

#35475308   2022/04/27 To Up

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.

Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years of age or older.
Steven W Pipe, Cédric Hermans, Meera Chitlur, Manuel Carcao, Giancarlo Castaman, Joanna A Davis, Jonathan Ducore, Amy L Dunn, Miguel Escobar, Janna Journeycake, Osman Khan, Johnny Mahlangu, Shannon L Meeks, Ismail Haroon Mitha, Claude Négrier, Ulrike Nowak-Göttl, Michael Recht, Tammuella Chrisentery-Singleton, Oleksandra Stasyshyn, Kateryna V Vilchevska, Laura Villarreal Martinez, Michael Wang, Jerzy Windyga, Guy Young, W Allan Alexander, Daniel Bonzo, Christopher Macie, Ian S Mitchell, Evelyne Sauty, Thomas A Wilkinson, Amy D Shapiro

1614 related Products with: Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.

2.50 nmol1100ug100ug100ug Lyophilized100 μg100ug0.1 mg

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

#35469831   2022/04/22 To Up

Synthetic Antibodies Detect Distinct Cellular States of Chromosome Passenger Complex Proteins.

High performance affinity reagents are essential tools to enable biologists to profile the cellular location and composition of macromolecular complexes undergoing dynamic reorganization. To support further development of such tools, we have assembled a high-throughput phage display pipeline to generate Fab-based affinity reagents that target different dynamic forms of a large macromolecular complex, using the Chromosomal Passenger Complex (CPC), as an example. The CPC is critical for the maintenance of chromosomal and cytoskeleton processes during cell division. The complex contains 4 protein components: Aurora B kinase, survivin, borealin and INCENP. The CPC acts as a node to dynamically organize other partnering subcomplexes to build multiple functional structures during mitotic progression. Using phage display mutagenesis, a cohort of synthetic antibodies (sABs) were generated against different domains of survivin, borealin and INCENP. Immunofluorescence established that a set of these sABs can discriminate between the form of the CPC complex in the midbody versus the spindle. Others localize to targets, which appear to be less organized, in the nucleus or cytoplasm. This differentiation suggests that different CPC epitopes have dynamic accessibility depending upon the mitotic state of the cell. An Immunoprecipitation/Mass Spectrometry analysis was performed using sABs that bound specifically to the CPC in either the midbody or MT spindle macromolecular assemblies. Thus, sABs can be exploited as high performance reagents to profile the accessibility of different components of the CPC within macromolecular assemblies during different stages of mitosis suggesting this high throughput approach will be applicable to other complex macromolecular systems.
Marcin Ura, Somnath Mukherjee, Edyta Marcon, Stefan A Koestler, Anthony A Kossiakoff

2372 related Products with: Synthetic Antibodies Detect Distinct Cellular States of Chromosome Passenger Complex Proteins.

100 ul0.1mg1mg1mg1mg1ml1 mg1mg1ml1mg1 mg

Related Pathways

paperclip

#35460250   // To Up

Expression-based Genome-wide Association Study Links OPN and IL1-RA With Newly Diagnosed Type 1 Diabetes in Children.

Islet autoantibodies (IAbs) are currently the most reliable indicators of islet autoimmunity. However, IAbs do not fully meet the need for the prediction and intervention of type 1 diabetes (T1D). Serological proteins should be great sources for biomarkers.
Xiaofan Jia, Kyoko Toda, Ling He, Dongmei Miao, Satoru Yamada, Liping Yu, Keiichi Kodama

2080 related Products with: Expression-based Genome-wide Association Study Links OPN and IL1-RA With Newly Diagnosed Type 1 Diabetes in Children.

100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug100ug100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized

Related Pathways

paperclip

#35443106   2022/04/20 To Up

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.

The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days.
Myron J Levin, Andrew Ustianowski, Stéphane De Wit, Odile Launay, Miles Avila, Alison Templeton, Yuan Yuan, Seth Seegobin, Adam Ellery, Dennis J Levinson, Philip Ambery, Rosalinda H Arends, Rohini Beavon, Kanika Dey, Pedro Garbes, Elizabeth J Kelly, Gavin C K W Koh, Karen A Near, Kelly W Padilla, Konstantina Psachoulia, Audrey Sharbaugh, Katie Streicher, Menelas N Pangalos, Mark T Esser,

2397 related Products with: Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.

5 lt5L96 Well5 mg 500 G 25 G25 µg10 mg 1000 ml 100ug

Related Pathways